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Abstract 
Background: This study uses multiple, contemporary methodologies to expand our knowledge of the 
temporal relationship between host-microbial interactions and clinical signs of gingivitis. 
Methods: Subgingival plaque and crevicular fluid samples were collected from 31 systemically healthy 
adults with naturally occurring plaque-induced gingivitis. Professional prophylaxis was administered and 
participants were followed over seven weeks. Microbial characterization was performed using a bead-
based hybridization assay and cytokine analysis using bead-based flow cytometry.  
Results: The provision of sequential interventions, oral hygiene instruction and subsequent professional 
prophylaxis brought about significant reduction of plaque and resolution of gingivitis at all post baseline 
points baseline (p<0.0001). Candidate cytokines that increased significantly (95% level) were interleukin 
(IL)-1β, matrix metalloproteinases (MMP)-1, MMP-3, MMP-8, MMP-9, from baseline to week 2; 
Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES) at week 4 and week 8; 
macrophage inflammatory protein (MIP)-1α and MIP-1β at week 8. Resolution of inflammation was 
accompanied by a shift in the microbiological flora towards those species associated with health.   
Conclusion: This study provides further evidence of the dynamic relationships that exist between the 
overt clinical signs, the microbial biofilm and the host response in gingivitis and upon resolution following 
clinical interventions.  Understanding the interactions between the host immune system and subgingival 
microbial communities during the resolution of established gingivitis continues to evolve as additional 
knowledge is achieved through using new analytical technologies. The present study confirms a critical 
effect of oral hygiene measures on restoration of microbial eubiosis in subgingival communities, 
confirming the important role for home care and professional intervention in maintaining oral health. 
Keywords:  Gingivitis; microbial interactions; cytokines. 
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Introduction 
Predicting progression from gingivitis to pathological attachment loss is challenging. Gingivitis provides 
a useful model to examine the complex interactions and response between the host and biofilm, 
particularly on resolution.  Clinically, gingivitis is addressed with hygiene phase therapy and/or 
professional prophylaxis to reduce the volume and composition of the acquired biofilm to a level that is 
at equilibrium with the host’s defences and does not lead to tissue destruction 1.  Classical trials have 
evaluated the effectiveness of hygiene phase therapy and professional prophylaxis from a clinical, 
biochemical or a microbiological perspective, but infrequently have studies correlated multiple 
outcomes2-5.  Further, studies have assessed shifts in biomarker panels to evaluate the relationships 
between bacteria and their hosts in health and diseased participants with more recent attempts to 
correlate the clinical picture with biological markers and bacterial species 1, 6-8.  Combinations of 
suspension bead multiplexing for inflammatory biomarker identification and 16s RNA cloning and 
sequencing allow for identification of multiple host inflammatory mediators and bacteria and have the 
potential to significantly improve the quantity of the data available to compare with clinical outcomes.  
 
In this study we have used naturally-occurring gingivitis in conjunction with immunoadsorbant bead, 
cytokine multiplexing tools to simultaneously analyse 11 inflammatory mediators in gingival crevicular 
fluid (GCF) samples to evaluate the changes in the GCF composition over time. We also used barcode 
magnetic bead-probe coupling and hybridisation with polymerise chain reaction (PCR) to profile the 
associated microflora. 
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 Materials and Methods 
This was an open label (non-blinded) longitudinal design study.  It was reviewed and given a favourable 
opinion by the Sunderland Research Ethics Committee, United Kingdom (Ref. 10/H0904/2) and 
conducted in accordance with ICH Good Clinical Practice (GCP) guidelines encompasing the Helsinki 
Declaration of 1975, as revised in 2000.  Local approval was provided through Newcastle Upon Tyne NHS 
Foundation Trust’s Research and Development Office.  The study was insured by ACE Insurance and 
Chartis Europe and onsite monitoring was carried out by Harrison Clinical Research Limited (UK).  
Participants were recruited from staff and students within Newcastle Dental Hospital and the School of 
Dental Sciences, Newcastle University (UK). 
 
Design 
This 8-week, longitudinal study comprised 7 study visits (between 01.02.13 and 28.03.13) (Figure 1).  
Visits 1 and 2 were permitted to be on the same day.  Participants were screened for suitability and 
written informed consent was obtained if they satisfied the inclusion criteria: 
Adults 18-65 years; in generally good health; have a minimum of 20 natural teeth; be a regular 
manual toothbrush user; able to comply with study protocol; gingival index9 ≥ 2 on at least 20 
sites; non-smoker. 
The following exclusion criteria were applied: 
Infectious or systemic diseases, diabetes mellitus; unable to comply with study protocol; 
pregnancy or nursing of infants; undergoing extensive dental, periodontal, orthodontic or 
implant treatment; had a cardiac pacemaker or automatic implanted cardiac defibrillator; 
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received antimicrobials within 3 weeks of enrolment; anti-inflammatory or anti-coagulant 
medication; whole mouth average Löe and Silness Gingival Index of ˃2.5; had sites of concurrent 
attachment loss of ˃1.0mm at ˃ 5 sites in any one quadrant (to exclude Participants with 
extensive gingival recession); heavy deposits of calculus, extensive crown or bridge work and/or 
extensive caries; using bleaching trays or professional whitening treatment; unwilling to abstain 
from using mouthrinses, dental floss, toothpastes (other than the assigned product) or other 
toothbrushes for the duration of the study; oral surgery within 6 months of enrolment; 
orthodontic brackets; received a dental prophylaxis within 1 month prior to enrolment; oral or 
extra-oral piercing with ornament or accessory in/or surrounding the oral cavity; been a 
participant in a dental research study within the previous 20 days prior to enrolment; were a 
current or regular user of an electronic/power/battery toothbrush (prior periodic use or in other 
studies permitted) at time of enrolment; were employed by a company that produces, distributes 
or markets dental products. 
 
Those fulfilling these criteria attended appointments at baseline (within 14 days of screening), and follow 
up at 2, 4, 6 and 8 weeks.  Participants were instructed to brush their teeth within 2-6 hours prior to 
each appointment.  At each visit the medical and dental histories were reviewed, compliance checked 
(brushing diary) along with an intra-oral soft tissue examination.  At baseline, 4 and 8 weeks plaque index 
(PI) 10, gingival index (GI) 9 and probing depth (PD) (in that order) were recorded before GCF, supra and 
sub gingival plaque samples were collected.  At 2 and 6 weeks PI and GI were recorded and GCF samples 
taken.  
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Calibration 
Prior to commencement, calibration of 2 clinical examiners was performed on the three clinical indices: 
PI, GI and PD.  A weighted Cohen’s kappa statistic was used to assess the agreement between two raters 
after adjusting for chance 11.  The weighted kappa for the clinical parameters was: PI=0.80 [95% CI 0.75, 
0.84]; GI = 0.77 [0.70, 0.82]; PD = 0.84 [95% CI 0.78, 0.82]. 
 
Power and sample size 
GI, being the clinical measure of inflammation, was considered to be the primary clinical outcome for 
the purposes of calculating sample size. The study was designed to have a high power of detecting a 
moderate change in mean GI over time.  The assumption was made that a standard deviation of 0.2 was 
a reasonable estimate of the within group standard deviation.  30 participants would be required to 
detect with 90% power a mean GI change of 0.12 or greater.   
 
Sample collection 
Samples were collected from 2 sites around 8 teeth in each participant. A quadrant/tooth/site (QTS) 
notation was used for site nomenclature and identification with the same sites being used for both GCF 
and plaque collection for microbial assessment: 171/163 (that is, upper right/second permanent 
molar/mesiobuccal and upper right/first permanent molar/distobuccal), 271/263, 371/363, 471/463.  If 
one of the target teeth was absent (or had a non-inflamed site), a sample was taken from the next 
available (mesial) tooth.  All sites were therefore inflamed and the same sites were used throughout the 
study.  
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Sample sites were isolated and dried, GCF was collected using Periopaper® collection strips (Oraflow, 
Smithtown, NY, USA).  The Periopaper® was left in place for 30-60 seconds or until the paper visibly 
dampened at the lower third.  The paper was then removed and the volume determined using a 
calibrated Periotron 8000*.  Samples were wrapped in autoclaved aluminium foil and placed into two 
barcoded 2mL Eppendorf microfuge tubes.  The sample tubes were pre-labelled with unique identifiers 
for the study and specimen.  Samples were flash frozen in liquid nitrogen and placed in a temperature 
controlled freezer (-80°C) until shipment on dry ice and storage in liquid nitrogen until mediator analysis. 
Supragingival plaque was collected from the target sites by sweeping a Gracey curette at the first site 
and wiping onto 2 paper points.  Subgingival plaque samples were collected by inserting 5 paper points‡ 
simultaneously into the gingival sulcus of the site for 10 seconds.  Following removal of the paper points, 
the sulcus was swept with the curette and the plaque wiped onto the same points.  All paper points from 
any one site were then placed into the pre-labelled cryovial and the procedure repeated for the 
subsequent sites in the remaining quadrants.   Samples were placed into barcoded (for participant 
number, site and visit) 2 mL Eppendorf microcentrifuge tubes and placed in a temperature controlled 
freezer at -80°C until shipment on dry ice and analysis. 
 
Interventions 
Hygiene phase therapy 
At baseline, all participants were provided with toothbrushing instruction by one clinician.  They received 
a powered toothbrush§.  They were given comprehensive, standardised written and verbal instructions 
Footnote: *Oraflow, Smithtown, New York, USA. 
   Dentsply, Weybridge, Surrey, UK. 
  ‡ Dentsply Maillefer, Ballaigues, Switzerland. 
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to brush their teeth twice daily for 2 minutes using a standardised toothpaste Colgate Cavity Protection¶.  
No instructions for interdental cleaning were given. 
Professional prophylaxis 
The second intervention was provided at a single visit at week 4.  Full mouth scaling and prophylaxis# to 
remove supra and subgingival plaque and calculus deposits was undertaken by a single dental hygienist. 
 
Analysis of GCF inflammatory mediators 
Analysis of the GCF samples took place at the University of North Carolina (UNC) cytokine analysis facility, 
Chapel Hill, USA.  Two samples per participant visit (463,471) were prepared and analysed separately for 
the following mediators: interleukin (IL)-1, IL-1, IL-2, matrix metalloproteinase (MMP)-1, MMP-3, 
MMP-8, MMP-9, MMP-13, Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES), 
and macrophage inflammatory protein (MIP)-1, MIP1.  Analysis was performed to quantify the levels 
of inflammatory mediators using the Fluorokine Profiling (MAP) cytokine multiplex kits** and the Bio-
Plex 200 analyser system.  The cytokines IL-1, IL-1, IL-2, MIP-1, MIP-1 were analysed using 
Fluorokine MAP multi analyte profiling human base kit A and the matrix metalloproteinases (MMP-1, 
MMP-3, MMP-8, MMP-9, MMP-13) were analysed using human MMP base kit (R&D Systems, MN, USA) 
as previously described 6, 7.  All biomarker values were then corrected for elution volume, assay dilution 
and GCF volume and expressed as a GCF concentration. 
 
Footnote: § Sonicare FlexCare HX6942/20 with ProResults brush head (Philips Consumer Lifestyle, Bothell, Washington, 
USA).  
¶Colgate-Palmolive, Guildford, Surrey, UK 
#prophylaxis paste, Kemdent®, UK. **R&D Systems, Minneapolis, USA. 
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Analysis of microbial composition 
Analysis of the plaque samples was carried out at the College of Dentistry, The Ohio State University, 
OH, USA.  Analysis of the plaque samples was undertaken on pooled samples from one quadrant for 
each participant for each visit, as previously described 12. 
Supra and subgingival bacteria were separated from the paper points by adding 200 µL phosphate 
buffered saline (PBS) to the tubes and agitating at 450 rpm using a microplate shaker.  The points were 
removed and bacterial DNA isolated with a DNA MiniAmp Kit‡‡, using the tissue protocol according to 
the manufacturer’s instructions.  The community DNA was amplified using two broad range 16S primers, 
785R (5'-GAC TAC CAG GGT ATC TAA TCC-3') and A17 (5’-GTT TGA TCC TGG CTC AG -3’).  The reverse 
primer (785R) was modified to contain a 5’-biotin, 12-carbon linker and five phosphothiorate bonds. PCR 
was performed with the following cycling conditions: denaturation at 94°C for 1 minute, annealing at 
42°C for 2 minutes, and elongation at 72°C for 3 minutes. A final, 10-minute elongation at 72°C followed 
22 cycles of amplification. PCR products were purified using a commercially available kit§§. Agarose gel 
electrophoresis was used to confirm successful amplification of the bacterial DNA. 
Barcode magnetic bead –probe coupling and hybridisation 
Bacteria specific capture probes were covalently coupled to a specific set of carboxyl magnetic beads as 
described in the manufacturer’s protocol: Applied BioCode System ¶¶.  The bead-bound probes were 
then hybridised to the biotin labelled PCR product prior to the addition of streptavidin-r-phycoerythrin 
conjugate (SA-PE) and detection buffer to hybridise the target and allow detection using a BioCode 1000 
analyser13.  Images were decoded for individual bead and intensity of fluorescence; which is directly 
 Footnote: 
 Luminex Corporation, DeSoto, Texas, USA. 
  **R&D Systems, Minneapolis, USA. 
  ‡‡ Qiagen, Valencia, California, USA. 
  §§ QIAquick PCR purification, Quiagen, Valencia, California, USA. 
  ¶¶  Applied Biocode Inc., California, USA 
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related to microbial levels in the sample. 
Analytical plan 
The population to be analysed comprised all enrolled participants with available post-baseline date.  
Analyses were conducted using SAS/STAT® software.  Continuous variables were summarized using 
descriptive statistics.  PI, GI, PD were analysed using analysis of variance (ANOVA).  The biomarker data 
were summarised using descriptive statistics for the observed values and the changes from baseline.   
Inflammatory mediator analysis was performed blinded to the sample, visit and participants identifiers. 
Descriptive statistics were produced for each mediator including mean values and standard deviations 
for each participants at each visit.  The values obtained were log transformed as they were not normally 
distributed following correction for elution volume, assay dilution and GCF volume.  Log mean values of 
mediator concentrations in picograms per millilitre were calculated for comparison.   
Microbial laboratory analysis was performed blinded to the sample, visit and participants identifiers.  
Following examination of the distribution, the microbial data were log 10 transformed prior to analysis.   
For the biomarker and microbial data, two sided t-tests without adjustments for multiple comparisons, 
were used to assess statistical significance of changes from baseline. 
 
Results 
Clinical 
31 participants were screened, fulfilled the eligibility criteria and were consented to participate.  All 31 
participants were retained through the 7-visit protocol with no early terminations or serious adverse 
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events.  The participants were mostly female (67%) and white (83.9%).  The mean age was 27 years.  The 
overall mean for PI, GI and PDs were calculated as an arithmetic average of all characteristic scores at 6 
sites per tooth.  There was a consistent reduction in PI and GI from baseline following each intervention 
which was sustained to the completion of the study (Table 2). At baseline the mean clinical data were PI 
= 1.1 and GI = 1.0 with reduction at 8 weeks to PI = 0.40 and GI = 0.40.  Reductions at all post-baseline 
points showed statistically significant improvements from baseline (p<0.0001).  PDs did not change 
significantly; baseline mean PD = 1.9 and at 8 weeks 1.8 (p = 0.1266). 
Microbial data 
Descriptive statistics (mean, standard error, 95% confidence intervals and p values) for the 10 
supragingival and 8 subgingival microbial species with significant reductions (p < 0.05) from baseline are 
presented in Table 4. Descriptive statistics for the 6 supragingival and 3 subgingival microbial species 
with significant increases (p < 0.05) from baseline are presented in Table 5.  Both  supra- and subgingival 
pathogens showed significant reductions (p=0.05) at weeks 4 and 8 when compared to baseline; highly 
significant reductions (p<0.001) were identified for subgingival samples of Campylobacter gracilis (weeks 
4 and 8), Capnocytophaga ochracea (week 8), Dialister pneumonistes (weeks 4 and 8), Selenomonas 
noxia (weeks 4 and 8) and Treponema denticola (week 8).  In the supragingival environment only 
Selenomonas sputigena showed highly significant reductions at weeks 4 and 8 compared to baseline.  Of 
the bacteria associated with health, there were highly significant increases (log-10 transformed data) in 
subgingival samples of Granulicatella adjacens and Veillonella parvula (weeks 4 and 8), Streptococcus 
mitis (week8), and supragingival early colonisers Streptococcus sanguinis (weeks 4 and 8). 
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GCF inflammatory mediators 
Change in GCF inflammatory mediators from baseline and associated p-values are given in Table 3.  
Whilst most inflammatory mediators increased transiently, few showed significant differences from 
baseline at any week.  Those that did show statistical significance at the 95% level were IL-1β, MMP-1, 
MMP-3, MMP-8, MMP-9, from baseline to week 2, RANTES at week 4 and week 8; MIP-1α and MIP-1β 
at week 8.  There were transient changes following the interventions at baseline and week 4 for some 
mediators.  No mediators showed a sustained change from baseline when examining the collated data 
or when all inflammatory mediators were considered together and no significant differences were 
detected over time (p>0.05). 
 
Discussion 
Inflammation occurs in gingival tissue in response to adjacent plaque bacterial biofilm and the 
accumulation of endotoxins.  At the tissue and cellular level, there is an influx of cells (neutrophils and 
macrophages) from the peripheral blood to the gingival crevice.  The cytokines (IL-1α, IL-1β and IL-8) and 
chemokines (MIP-1α, MIP-1β, and RANTES) play a role in activating and recruiting these inflammatory 
cells to the site of infection7.  The MMPs are enzymes involved in the destruction of periodontal tissue 
and are often associated with more advanced stages of periodontal disease and overt clinical signs 14. 
In this study, the a priori hypothesis was that reductions in inflammation after hygiene phase treatment 
and instrumentation are concomitant with reductions in subclinical levels of cytokine, chemokine and 
MMP biomarkers.  Whilst there were clinical improvements following each intervention there were no 
significant temporal reductions in inflammatory mediators.  The absence of statistically significant 
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differences in levels of specific inflammatory biomarkers may be due to high biological variance in 
participants’ genetic disposition (better or poorer responders to treatment than others), microbial flora 
in inflamed sites, the absence of pronounced inflammation in participants, all of which reduce the power 
to detect treatment effects.  Aspiras at al. hypothesised that transient cycles of non-significant trends in 
biomarkers might be detected as the host modulates microbial killing but at the same time limiting tissue 
damage 15. 
A number of biomarkers were observed to increase at week 2 (following the first intervention), decrease 
at week 4 and then a repeat in this trend at weeks 6 and 8 (following the second intervention). There 
were some reductions of individual cytokines and chemokine biomarkers from baseline, but these were 
neither significant nor sustained throughout the study.  Honda et al. found that IL-1β may play a different 
role in gingivitis to that in more advanced periodontitis 16.  IL-1β is known to up-regulate tissue turnover; 
it may not necessarily induce tissue destruction in gingivitis lesions, but may stimulate MMPs at the same 
time 17.  Inflammatory biomarkers are not necessarily always pathogenic and exhibit different functions, 
for example MMPs being involved in tissue remodelling in excess can drive and exacerbate inflammation. 
Previous work on experimental gingivitis transcriptome and salivary markers has shown that the 
induction of gingivitis is associated with a suppression of chemokines- especially those associated with 
neutrophil recruitment 7.  This work also suggests a suppression of chemokine expression in naturally 
occurring gingivitis which may be a disruption of the normal influx and function of neutrophil mediated 
bacterial clearance 7.  These observations are consistent with previous findings that treating gingivitis, 
either naturally occurring or experimental, tends to increase the levels of the chemokines to restore the 
neutrophil tissue flux back to normal 7.  Only a trend can be seen here with the increases in, for example, 
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IL-8, MIP-1 β, and RANTES. It is also noted that MMP-8 which is a reliable marker for neutrophils also 
increases. If these markers are considered as a chemotactic class or group then it would be expected 
that they would increase with treatment. Even this small increase can be seen as a restoration of the 
normal chemokine balance for the tissues, helping to restore them to health. 
The changes in microbial populations following hygiene phase treatment either brushing alone or with 
adjunctive professional prophylaxis are consistent with previous studies 7, 8 and indicate a progressive 
increase in the proportion of bacteria associated with disease to those associated with health in both 
supragingival and subgingival plaque 1.  These microbial shifts generally precede clinical changes that are 
indicative of disease development or resolution. In this study, this is apparent post-intervention with 
significant increases observed with oral commensals such as Granulicatella adjacens and early colonisers 
such as Streptococcus mitis, Streptococcus sanguinis and Veillonella parvula in supra- and subgingival 
samples.  The abundance of oral commensals would be expected to decrease with the severity of 
periodontal diseases as the complexity of the biofilm increases towards facultative anaerobic and 
anaerobic species.  The increase in subgingival Prevotella nigrescens is an unusual finding, as this would 
ordinarily decrease in health and has been reported to trigger an overactive immune response 18.   
Decreases in bacteria associated with later colonisation, such as Campylobacter gracilis, 
Capnocytophaga ochracea were observed, together with reductions in subgingival species associated 
with periodontal diseases such as Dialister pneumosintes, Selenomonas noxia and Treponema denticola 
19-21.  
The effect of the two sequential interventions drove a change in the composition of plaque in favour of 
those species associated with health that are aerobic and enhance the antagonistic relationship that 
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exists between pathogenic and non-pathogenic species 19, 22, 23.  Compliance with the plaque control 
intervention, supplemented by professional prophylaxis may account for the increased levels of early 
colonisers and commensals, decrease in disease associated species, and concomitant clinical 
observations of plaque reduction and improved gingival health 24, 25.  These findings are consistent with 
previous evidence that suboptimal supragingival plaque control affects the quantity of plaque biofilm 
and also its composition 26.  
The bacterial content of the pocket is an important factor in gene expression in the gingival tissues and 
therefore, influence the clinical phenotype and inflammatory response.  Pathogenic bacteria may 
directly upregulate only a few genes responsible for a generalised non-specific inflammatory response 
while regulating a larger set of genes responsible for localised cellular responses unique to each 
bacterium in the biofilm 7. Such variation in the microbial-host gene regulation could explain why a small 
change in biomarker activity for one individual may not translate to an equivalent degree of clinical 
change in another. It also reinforces the challenges of ascribing predictable trends of some biomarker 
behaviours to specific periodontal disease states or indeed generally to inflammatory disease. 
Previous work has suggested that changes in levels of microbial and chemical biomarkers are indicative 
of future clinical patterns in health and disease 3, 7.  A clear and unequivocal association between changes 
in the microflora and inflammatory mediators was not, however, identified in this study and a longer 
study beyond 8 weeks post-intervention might be needed to support correlations between the clinical 
and subclinical metrics. Such a study might bring the associated risks of non-compliance with study 
protocols. 
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Conclusion 
The provision of sequential interventions, oral hygiene (toothbrushing) instruction and subsequent 
professional prophylaxis brought about predicted, significant improvements in the clinical signs of 
gingivitis.  A shift in the microbiological flora towards those species associated with health was observed 
following the interventions however there were no significant difference in local levels of biological 
markers of inflammation (cytokines, MMPs).  This study provides further evidence of the dynamic 
relationship between overt clinical signs of gingival inflammation and the microbial biofilm upon 
resolution of gingivitis. An association between the bacterial response and the host response, however, 
is less obvious and needs further investigation. 
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 Actinomyces naeslundii  Enterococcus faecalis  Neisseria mucosa  Streptococcus mitis  
Actinomyces odontolyticus  Eubacterium brachy  Parvimonas micra  Streptococcus mutans  
Actinomyces viscosus  Eubacterium saburreum  Porphyromonas gingivalis  Streptococcus sanguinis  
Aggregatibacter 
actinomycetemcomitans  
Fillifactor alocis  Prevotella nigrescens  Tannerella forsythia 
Bifidobacterium infantis  Fusobacterium nucleatum  Prevotella oris  Treponema denticola  
Campylobacter gracilis  Granulicatella adjacens  
Propionibacterium 
propionicus  
Veillonella parvula  
Capnocytophaga ochracea  Lactobacillus gasseri Pseudomonas aeruginosa  
 
Catonella morbi  Lactobacillus reuteri  Selenomonas noxia   
Dialister pneumosintes  Leptotrichia buccalis  Selenomonas sputigena  
 
 
Table 1.  List of all bacterial DNA probes used in the microbial analysis of supra- and sub-gingival plaque samples. 
  
 
 
 
Hygiene phase       Professional prophylaxis 
 
 Baseline 2 weeks 4 weeks 6 weeks 8 weeks 
Mean PI  1.1 (0.41) 0.7 (0.37)* 0.6 (0.32)* 0.4 (0.26)* 0.4 (0.21)* 
 
Mean GI  1.0 (0.19) 0.8 (0.21)* 0.7 (0.15)* 0.5 (0.15)* 0.4 (0.13)* 
       
Mean PD  1.9 (0.24) 
 
1.9 (0.18) 
 
1.8 (0.20) 
 
Table 2. Mean (SE) Plaque Index (PI), Gingival Index (GI) and Probing Depths throughout the study. Interventions took place 
following Baseline and week 4. 
*Indicates significant difference from baseline ANOVA p<0.0001 
  
 Mediator level: Log mean pg/mL (SD) 
  Hygiene phase Professional prophylaxis 
 Baseline Week 2 Week 4 Week 6 Week 8 
IL-1α 5.07 (0.64) 5.16 (0.58) 5.23 (0.58) 5.12 (0.66) 5.22 (0.63) 
p-value  0.434 0.236 0.676 0.343 
IL-1β 4.57 (0.63) 4.81 (0.62) 4.76 (0.66) 4.81 (0.66) 4.77 (0.70) 
p-value  0.050 0.152 0.096 0.211 
IL-8 5.38 (0.52) 5.60 (0.61) 5.56 (0.51) 5.60 (0.64) 5.58 (0.54) 
p-value  0.092 0.115 0.195 0.146 
MIP-1α 3.83 (0.44) 4.03 (0.53) 4.03 (0.61) 4.00 (0.46) 4.07 (0.53) 
p-value  0.086 0.109 0.161 0.027 
MIP-1β 3.38 (0.59) 3.66 (0.74) 3.58 (0.69) 3.60 (0.63) 3.69 (0.68) 
p-value  0.101 0.146 0.196 0.028 
RANTES 3.58 (0.51) 3.69 (0.42) 3.92 (0.64) 3.73 (0.36) 3.87 (0.45) 
p-value  0.287 0.014 0.186 0.014 
MMP-1 4.56 (0.82) 4.94 (0.66) 4.53 (0.62) 4.83 (0.82) 4.73 (0.78) 
p-value  0.021 0.886 0.156 0.360 
MMP-3 4.26 (0.74) 4.60 (0.67) 4.24 (0.58) 4.43 (0.73) 4.30 (0.72) 
p-value  0.025 0.894 0.312 0.799 
MMP-8 7.11 (0.76) 7.68 (0.54) 7.10 (0.70) 7.51 (0.81) 7.16 (0.71) 
p-value  0.001 0.963 0.057 0.792 
MMP-9 7.67 (0.74) 8.15 (0.54) 7.68 (0.68) 7.98 (0.81) 7.74 (0.79) 
p-value  0.005 0.921 0.145 0.651 
MMP-13 5.23 (0.86) 5.39 (0.90) 5.26 (0.82) 5.41 (0.91) 5.44 (0.95) 
p-value  0.296 0.851 0.329 0.264 
 
Table 3. Log mean transformed mediator concentrations in GCF for 31 participants at all time points over the 8 weeks of the 
study.  P-values are based on two-sided t-tests. 
IL   Interleukin 
MIP   Macrophage inflammatory protein 
MMP   Matrix metalloproteinase 
RANTES      Regulated on Activation, Normal T cell Expressed and Secreted 
 
  
Bacteria Visit n 
Least Square Mean 
(SE) 
Reduction 
95% Confidence 
Interval 
p-value 
Subgingival sample      
Actinomyces viscosus Week 8  27 0.13 (  0.05) ( 0.04,   0.22) 0.008 
Campylobacter gracilis Week 4  27 0.34 (  0.08) ( 0.17,   0.51) <0.001 
 Week 8  27 0.41 (  0.08) ( 0.24,   0.58) <0.001 
Capnocytophaga ochracea Week 8  27 0.31 (  0.08) ( 0.15,   0.47) <0.001 
Dialister pneumonistes Week 4  27 0.63 (  0.11) ( 0.40,   0.87) <0.001 
 Week 8  27 0.59 (  0.11) ( 0.36,   0.83) <0.001 
Eubacterium saburreum Week 4  27 0.18 (  0.07) ( 0.02,   0.33) 0.027 
 Week 8  27 0.20 (  0.07) ( 0.04,   0.35) 0.014 
Parvimonas micra Week 4  27 0.19 (  0.07) ( 0.04,   0.33) 0.012 
 Week 8  27 0.19 (  0.07) ( 0.05,   0.33) 0.012 
Selenomonas noxia Week 4  27 0.35 (  0.09) ( 0.17,   0.52) <0.001 
 Week 8  27 0.41 (  0.09) ( 0.23,   0.58) <0.001 
Treponema denticola Week 4 27 0.25 (  0.08) ( 0.08,   0.42) 0.005 
 Week 8  27 0.39 (  0.08) ( 0.23,   0.56) <0..001 
Supragingival samples      
Actinomyces odontilyticus Week 8  27 0.12 (  0.05) ( 0.03,   0.21) 0.015 
Campylobacter gracilis Week 4  27 0.17 (  0.07) ( 0.03,   0.32) 0.017 
 Week 8  27 0.21 (  0.07) ( 0.07,   0.35) 0.005 
Eubacterium brachy Week 8  27 0.18 (  0.08) ( 0.03,   0.34) 0.024 
Eubacterium saburreum Week 8  27 0.13 (  0.05) ( 0.02,   0.25) 0.020 
Lactobacillus gasseri Week 8  27 0.17 (  0.05) ( 0.06,   0.27) 0.003 
Prevotella nigrescens Week 4  27 0.09 (  0.04) ( 0.01,   0.16) 0.023 
Selenomonas noxia Week 4  27 0.18 (  0.08) ( 0.01,   0.34) 0.039 
Selenomonas sputigena Week 4  27 0.44 (  0.12) ( 0.19,   0.68) 0.001 
 Week 8  27 0.50 (  0.12) ( 0.25,   0.74) <0.001 
Streptococcus mutans Week 8  27 0.10 (  0.04) ( 0.02,   0.18) 0.014 
Tannerella forsythia Week 8  27 0.08 (  0.04) ( 0.01,   0.15) 0.036 
Table 4.  Descriptive summary of log-10 transformed sub- and supra-gingival bacterial data with significant reductions from 
baseline.  P-value based on a two sided t-test  
Bacteria Visit n 
Least Square 
Mean (SE) 
Reduction 
95% Confidence 
Interval 
p-value 
Subgingival      
Granulicatella adjacens Week 4 27 -0.19 (  0.04) (-0.28,  -0.10) <0.001 
 Week 8 27 -0.19 (  0.04) (-0.28,  -0.09) <0.001 
Neisseria mucosa Week 4 27 -0.15 (  0.06) (-0.27,  -0.02) 0.025 
 Week 8 27 -0.16 (  0.06) (-0.29,  -0.03) 0.016 
Prevotella nigrescens Week 4 27 -0.13 (  0.06) (-0.25,  -0.01) 0.031 
 Week 8  27 -0.12 (  0.06) (-0.23,  -0.00) 0.047 
Streptococcus mitis Week 4  27 -0.30 (  0.11) (-0.54,  -0.07) 0.014 
 Week 8  27 -0.42 (  0.11) (-0.66,  -0.19) 0.001 
Streptococcus sanguinis Week 4  27 -0.31 (  0.09) (-0.49,  -0.13) 0.002 
 Week 8  27 -0.34 (  0.09) (-0.52,  -0.16) 0.001 
Veillonella parvula Week 4  27 -0.31 (  0.07) (-0.45,  -0.18) <0.001 
 Week 8 27 -0.35 (  0.07) (-0.48,  -0.21) <0.001 
Supragingival      
Streptococcus mitis Week 4  27 -0.21 (  0.08) (-0.37,  -0.04) 0.019 
 Week 8  27 -0.19 (  0.08) (-0.36,  -0.02) 0.027 
Streptococcus sanguinis Week 4  27 -0.39 (  0.09) (-0.57,  -0.20) <0.001 
 Week 8  27 -0.40 (  0.09) (-0.58,  -0.21) <0.001 
Veillonella parvula Week 4  27 -0.23 (  0.09) (-0.42,  -0.03) 0.023 
 Week 8  27 -0.20 (  0.09) (-0.39,  -0.01) 0.044 
Table 5. Descriptive summary of log-10 transformed sub- and supra-gingival bacterial data with significant increases from 
baseline.  P-value based on a two sided t-test   
Figure 1.  Study overview of an 8 week longitudinal study to characterise and correlate clinical, microbial and host response 
parameters in participants with established gingivitis, participants received the same two sequential interventions. 
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INTERVENTION PHASE II 
INTERVENTION PHASE I 
Visit 1 
Consent 
Visit 2 
Screening 
Visit 3 
Baseline; Day 0 
Visit 4 
Week 2; Day 14 
(±3 Days) 
Visit 5 
Week 4; Day 28 
(±3 Days) 
Visit 6 
Week 6; Day 42 
(±3 Days) 
Visit 7 
Week 8; Day 56 
(±3 Days) 
Visit 1:  
Informed consent 
Visit 2:  
Medical/dental history 
Demographics: height/weight/gender/race 
Body mass index 
Soft tissue examination 
Gingival Index 
Periodontal assessments (PPD, CAL) 
Eligibility criteria met 
Enrolment 
Visit 3:  
Safety monitoring/adverse events 
Plaque Index 
Supragingival plaque samples 
GCF 
Subgingival plaque samples 
Gingival Index 
Periodontal probing depths 
Intervention 1: Hygiene phase therapy 
Issue participant diary 
Visit 4:  
Compliance check 
Safety monitoring/adverse events 
Plaque Index 
GCF  
Gingival Index 
Visit 6:  
Compliance check 
Safety monitoring/adverse events 
Plaque Index 
GCF  
Gingival Index 
Visit 7: 
Compliance check 
Safety monitoring/adverse events 
Plaque Index 
Supragingival plaque samples 
GCF 
Subgingival plaque samples 
Gingival Index 
Periodontal probing depths 
Remuneration 
Participant dismissed 
Visit 5:  
Safety monitoring/adverse events 
Plaque Index 
Supragingival plaque samples 
GCF 
Subgingival plaque samples 
Gingival Index 
Periodontal probing depths 
Intervention 2 professional prophylaxis 
Issue participant diary 
Figure legend. 
 
Figure 1.  Study overview of an 8-week longitudinal study to characterise and correlate clinical, 
microbial and host response parameters in participants with established gingivitis; participants 
received the same two sequential interventions. 
Table legends. 
Table 1.  List of all bacterial DNA probes used in the microbial analysis of supra- and sub-gingival 
plaque samples. 
 
Table 2.  Mean (SE) Plaque Index (PI), Gingival Index (GI) and Probing Depths throughout the study. 
Interventions took place following Baseline and week 4. 
*Indicates significant difference from baseline ANOVA p<0.0001 
 
Table 3.  Log mean transformed mediator concentrations in GCF for 31 participants at all time points 
over the 8 weeks of the study.  P-values are based on two-sided t-tests. 
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